Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06373133 | SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer | PHASE1 | NOT YET_RECRUITING | 36 | — | — | May 1, 2024 | Nov 1, 2026 | Apr 18, 2024 | - | — |
The dose is considered tolerable if the incidence of DLT is less than 33.3%.
Progression-free survival (PFS) denotes the chances of staying free of disease progression for a group of individuals suffering from a cancer after a particular treatment.
| Arm | Type | Description |
|---|---|---|
| SHR-8068+Adebrelimab+BP102 | EXPERIMENTAL | The first 9 subjects will be treated with low dose SHR-8068 (1mg/kg, q6w), and the subsequent subjects will be treated with high dose SHR-8068 (4mg/kg, q12w) if the toxicity of DLT is tolerable during the observation period. |
| Name | Type | Description |
|---|---|---|
| SHR-8068 | DRUG | 1mg/kg，ivgtt, d1, q6w or 4mg/kg，ivgtt, d1, q12w |
| Adebrelimab | DRUG | 1200mg, ivgtt, d1, q3w |
| BP102 | DRUG | 7.5mg/kg, ivgtt, d1, q3w |
Inclusion Criteria: 1. pathologically confirmed metastatic colorectal adenocarcinoma; 2. Age of 18-75 years old, both sexes; 3. predicted survival time ≥12 weeks; 4. Eastern Cooperative Oncology Group performance status (ECOG) score 0-2; 5. Participants who had failed second-line or higher standard...